MCID: NRM008
MIFTS: 27

Neuromyelitis Optica Spectrum Disorder

Categories: Rare diseases, Eye diseases, Neuronal diseases

Aliases & Classifications for Neuromyelitis Optica Spectrum Disorder

MalaCards integrated aliases for Neuromyelitis Optica Spectrum Disorder:

Name: Neuromyelitis Optica Spectrum Disorder 50
Neuromyelitis Optica 69
Nmosd 50

Classifications:



Summaries for Neuromyelitis Optica Spectrum Disorder

MalaCards based summary : Neuromyelitis Optica Spectrum Disorder, also known as neuromyelitis optica, is related to neuromyelitis optica and myelitis. An important gene associated with Neuromyelitis Optica Spectrum Disorder is AQP4 (Aquaporin 4). The drugs Mitoxantrone and Mycophenolate mofetil have been mentioned in the context of this disorder. Affiliated tissues include brain, b cells and spinal cord.

Related Diseases for Neuromyelitis Optica Spectrum Disorder

Diseases in the Neuromyelitis Optica family:

Neuromyelitis Optica Spectrum Disorder

Diseases related to Neuromyelitis Optica Spectrum Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 47)
id Related Disease Score Top Affiliating Genes
1 neuromyelitis optica 11.1
2 myelitis 10.4
3 optic neuritis 10.3
4 neuritis 10.3
5 transverse myelitis 10.2
6 cervicitis 10.2
7 retinitis 10.2
8 myasthenia gravis 10.1
9 cerebritis 10.1
10 lymphoma 10.0
11 sjogren's syndrome 10.0
12 internuclear ophthalmoplegia 10.0
13 systemic lupus erythematosus 9.9
14 biotinidase deficiency 9.9
15 b-cell lymphomas 9.9
16 follicular lymphoma 9.9
17 hemolytic anemia 9.9
18 hepatitis 9.9
19 hepatitis b 9.9
20 restless legs syndrome 9.9
21 aphasia 9.9
22 apraxia 9.9
23 dermatomyositis 9.9
24 parotitis 9.9
25 meningoencephalitis 9.9
26 acute cervicitis 9.9
27 cortical blindness 9.9
28 spondylosis 9.9
29 adenocarcinoma 9.9
30 purpura 9.9
31 tuberculosis 9.9
32 myopathy 9.9
33 connective tissue disease 9.9
34 mature b-cell neoplasm 9.9
35 thyroiditis 9.9
36 autoimmune hemolytic anemia 9.9
37 myocarditis 9.9
38 influenza 9.9
39 lupus erythematosus 9.9
40 encephalitis 9.9
41 neurosyphilis 9.9
42 postural orthostatic tachycardia syndrome 9.9
43 syndrome of inappropriate antidiuretic hormone 9.9
44 encephalopathy 9.9
45 hypersomnia 9.9
46 occipital neuralgia 9.9
47 methotrexate-associated lymphoproliferative disorders 9.9

Graphical network of the top 20 diseases related to Neuromyelitis Optica Spectrum Disorder:



Diseases related to Neuromyelitis Optica Spectrum Disorder

Symptoms & Phenotypes for Neuromyelitis Optica Spectrum Disorder

Drugs & Therapeutics for Neuromyelitis Optica Spectrum Disorder

Drugs for Neuromyelitis Optica Spectrum Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 79)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
2
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
3
Mycophenolic acid Approved Phase 4 24280-93-1 446541
4
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
5 Analgesics Phase 4
6 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1
7 Topoisomerase Inhibitors Phase 4
8 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1
9 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 1
10 glucocorticoids Phase 4,Phase 3,Phase 1
11 Hormone Antagonists Phase 4,Phase 3,Phase 1
12 Hormones Phase 4,Phase 3,Phase 1
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1
14 Immunosuppressive Agents Phase 4,Phase 2,Phase 3,Phase 1
15 Anti-Bacterial Agents Phase 4
16 Antibiotics, Antitubercular Phase 4
17
Methylprednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 83-43-2 6741
18
Prednisolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 50-24-8 5755
19
Azathioprine Approved Phase 2, Phase 3 446-86-6 2265
20
rituximab Approved Phase 2, Phase 3,Phase 1 174722-31-7 10201696
21 Antiemetics Phase 3,Phase 1
22 Autonomic Agents Phase 3,Phase 1
23 Gastrointestinal Agents Phase 3,Phase 1
24 Methylprednisolone acetate Phase 3,Phase 1,Phase 2
25 Methylprednisolone Hemisuccinate Phase 3,Phase 1,Phase 2
26 Neuroprotective Agents Phase 3,Phase 1
27 Prednisolone acetate Phase 3,Phase 1,Phase 2
28 Prednisolone hemisuccinate Phase 3,Phase 1,Phase 2
29 Prednisolone phosphate Phase 3,Phase 1,Phase 2
30 Protective Agents Phase 3,Phase 1
31 Antimetabolites Phase 2, Phase 3
32 Antimetabolites, Antineoplastic Phase 2, Phase 3
33 Antirheumatic Agents Phase 2, Phase 3,Phase 1
34 Antibodies Phase 2, Phase 3, Phase 1
35 Immunoglobulins Phase 2, Phase 3, Phase 1
36 gamma-Globulins Phase 3,Phase 2
37 Immunoglobulins, Intravenous Phase 3,Phase 2
38 Rho(D) Immune Globulin Phase 3,Phase 2
39 Antibodies, Monoclonal Phase 2, Phase 3,Phase 1
40
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754 657311
41
Metoclopramide Approved, Investigational Phase 2 364-62-5 4168
42
Cetirizine Approved Phase 1, Phase 2 83881-51-0 2678
43
Histamine Approved, Investigational Phase 1, Phase 2 75614-87-8, 51-45-6 774
44
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
45
Mesna Approved Phase 1, Phase 2 3375-50-6 598
46
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
47
4-Aminopyridine Approved Phase 2 504-24-5 1727
48
Dexamethasone Approved, Investigational, Vet_approved Phase 1, Phase 2 50-02-2 5743
49
Chlorpheniramine Phase 2 113-92-8, 132-22-9 2725
50 Cortisol succinate Phase 2

Interventional clinical trials:

(show all 42)

id Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Mitoxantrone in Patients With Refractory Neuromyelitis Optica and Spectrum Disorders Unknown status NCT02021825 Phase 4 Mitoxantrone
2 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic’s Disease) Completed NCT00304291 Phase 4 Mitoxantrone
3 Mycophenolate Mofetil Treatment With Neuromyelitis Optica Spectrum Disorders in Chinese Patients Enrolling by invitation NCT02809079 Phase 4 Mycophenolate mofetil;Prednisone
4 Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone Unknown status NCT00004645 Phase 3
5 Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD Patients Completed NCT03002038 Phase 2, Phase 3 Azathioprine;Rituximab
6 A Double-masked, Placebo-controlled Study With Open Label Period to Evaluate MEDI-551 in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02200770 Phase 2, Phase 3
7 Efficacy and Safety Study as Add-on Therapy of SA237 to Treat NMO and NMOSD Recruiting NCT02028884 Phase 3 SA237;Placebo
8 A Double Blind Trial To Evaluate The Safety And Efficacy Of Eculizumab In Relapsing NMO Patients (PREVENT Study) Active, not recruiting NCT01892345 Phase 3 Eculizumab
9 Efficacy and Safety Study as Monotherapy of SA237 to Treat NMO and NMOSD Active, not recruiting NCT02073279 Phase 3 SA237;Placebo
10 An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients Enrolling by invitation NCT02003144 Phase 3
11 A Multicentre randomiSed Controlled TRial of IntraVEnous Immunoglobulin Versus Standard Therapy for Transverse Myelitis Terminated NCT02398994 Phase 3 Intravenous Methylprednisolone;Intravenous Immunoglobulin
12 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Unknown status NCT02249676 Phase 2
13 Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Therapy for Patients With Progressive Multiple Sclerosis and Neuromyelitis Optica Unknown status NCT01364246 Phase 1, Phase 2
14 Phase II Clinical Trial of NPB-01 in Patients With Anti-aquaporin 4 Antibody Positive Neuromyelitis Optica Spectrum Disorder Not Provided Adequate Effect of Therapy to Steroids Plus Therapy. Completed NCT01845584 Phase 2 NPB-01
15 An Open Label Study of the Effects of Eculizumab in Neuromyelitis Optica Completed NCT00904826 Phase 1, Phase 2 Eculizumab
16 Neuromyelitis Optica (NMO) & Cetirizine Completed NCT02865018 Phase 1, Phase 2 cetirizine
17 Hematopoietic Stem Cell Transplant in Devic's Disease Recruiting NCT00787722 Phase 1, Phase 2
18 Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder Active, not recruiting NCT02893111 Phase 2 Bortezomib
19 A Longitudinal Study of ACTEMRA® (Tocilizumab) as Monotherapy in Highly Active NMOSD Active, not recruiting NCT03062579 Phase 1, Phase 2 Tocilizumab
20 Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch) Active, not recruiting NCT02166346 Phase 2 Dalfampridine;Placebo
21 Autologous Hematopoietic Stem Cell Transplant in Neuromyelitis Optica Terminated NCT01339455 Phase 1, Phase 2
22 Pilot Study of alpha1-antitrypsin to Treat Neuromyelitis Optica Relapses Unknown status NCT02087813 Phase 1 Alpha1-antitrypsin;methylprednisolone
23 Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations Completed NCT01777412 Phase 1 Bevacizumab
24 C1-esterase Inhibitor (Cinryze) for Acute Treatment of Neuromyelitis Optica Exacerbation Completed NCT01759602 Phase 1 C1-esterase inhibitor (Cinryze)
25 Safety and Tolerability of Rituximab in Neuromyelitis Optica Completed NCT00501748 Phase 1 Rituximab
26 Central Pain Study for ABX-1431 Recruiting NCT03138421 Phase 1 ABX-1431 HCl;Placebo
27 Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses Active, not recruiting NCT02276963 Phase 1 Ublituximab
28 Treatment of Multiple Sclerosis and Neuromyelitis Optica With Regulatory Dendritic Cell: Clinical Trial Phase 1 B Active, not recruiting NCT02283671 Phase 1
29 Evaluation of Neural Loss in Multiple Sclerosis and Neuromyelitis Optica Using High Resolution Oct Unknown status NCT01024985
30 Quantitation of McArdle's Sign and Evaluation of Specificity for Multiple Sclerosis Completed NCT03122873
31 Multimodel Magnetic Resonance Imaging (MRI)of Multiple Sclerosis and Neuromyelitis Optica Spectrum Disorders Recruiting NCT02836327
32 The French Cohort and Biobank of Devic's Neuromyelitis Optica and Related Neurological Disorders (NMOSD) (NOMADMUS) Recruiting NCT02850705
33 The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders Recruiting NCT01623076
34 The French Multiple Sclerosis Registry Recruiting NCT02889965
35 The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset Recruiting NCT02886377
36 Optical Coherence Tomography and Optic Neuritis (OCTON) Recruiting NCT02573792
37 Analysis of the Distribution of Regulatory B Cells in Blood of Multiple Sclerosis Patients Recruiting NCT02789670
38 Stem Cell Ophthalmology Treatment Study II Recruiting NCT03011541
39 Maintenance Plasma Exchange for Neuromyelitis Optica Active, not recruiting NCT01500681
40 Biobank For MS And Other Demyelinating Diseases Active, not recruiting NCT00445367
41 Pathologic-MRI Findings in Atypical IIDD Active, not recruiting NCT03121105
42 Stem Cell Ophthalmology Treatment Study Enrolling by invitation NCT01920867

Search NIH Clinical Center for Neuromyelitis Optica Spectrum Disorder

Genetic Tests for Neuromyelitis Optica Spectrum Disorder

Anatomical Context for Neuromyelitis Optica Spectrum Disorder

MalaCards organs/tissues related to Neuromyelitis Optica Spectrum Disorder:

39
Brain, B Cells, Spinal Cord, Eye, Hypothalamus, Amygdala, Monocytes

Publications for Neuromyelitis Optica Spectrum Disorder

Articles related to Neuromyelitis Optica Spectrum Disorder:

(show top 50) (show all 230)
id Title Authors Year
1
Comparisons of the efficacy and tolerability of mycophenolate mofetil and azathioprine as treatments for neuromyelitis optica and neuromyelitis optica spectrum disorder. ( 27783452 )
2017
2
Clinical characteristics of late-onset neuromyelitis optica spectrum disorder: A multicenter retrospective study in Korea. ( 28058965 )
2017
3
Bidirectional degeneration in the visual pathway in neuromyelitis optica spectrum disorder (NMOSD). ( 28823217 )
2017
4
Effectiveness and safety of immunosuppressive therapy in neuromyelitis optica spectrum disorder during pregnancy. ( 28477712 )
2017
5
Cortical blindness and not optic neuritis as a cause of vision loss in a SjAPgren's syndrome (SS) patient with the neuromyelitis optica spectrum disorder (NMOSD): Challenges of ascribing demyelinating syndromes to SS: a case report. ( 28834867 )
2017
6
Methotrexate-associated lymphoproliferative disorder in a patient with neuromyelitis optica spectrum disorder: An implication for pathogenesis mediated by Epstein-Barr virus. ( 28716244 )
2017
7
Metabolomic profiling of CSF in multiple sclerosis and neuromyelitis optica spectrum disorder by nuclear magnetic resonance. ( 28746356 )
2017
8
Neuromyelitis Optica Spectrum Disorders. ( 28391784 )
2017
9
Disruption of the leptomeningeal blood barrier in neuromyelitis optica spectrum disorder. ( 28451627 )
2017
10
Safety and Efficacy of Bortezomib in Patients With Highly Relapsing Neuromyelitis Optica Spectrum Disorder. ( 28692708 )
2017
11
Acute-Onset Severe Occipital Neuralgia Associated With High Cervical Lesion in Patients With Neuromyelitis Optica Spectrum Disorder. ( 28699327 )
2017
12
Neuromyelitis optica spectrum disorder diagnostic criteria: Sensitivity and specificity are both important. ( 28080211 )
2017
13
Pruritus may be a common symptom related to neuromyelitis optica spectrum disorders. ( 28427688 )
2017
14
Increased frequency of IL-6-producing non-classical monocytes in neuromyelitis optica spectrum disorder. ( 28946890 )
2017
15
LC-MS/MS Analysis of Erythrocyte Thiopurine Nucleotides and Their Association With Genetic Variants in Patients With Neuromyelitis Optica Spectrum Disorders Taking Azathioprine. ( 27941536 )
2017
16
Reply to letter to the editor: Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder by Pitarokoili and Gold. ( 28747150 )
2017
17
Aquaporin-4 serostatus does not predict response to immunotherapy in neuromyelitis optica spectrum disorders. ( 28857723 )
2017
18
Comparison of cognitive and brain grey matter volume profiles between multiple sclerosis and neuromyelitis optica spectrum disorder. ( 28846745 )
2017
19
Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody. ( 28803524 )
2017
20
Anti-N-methyl-D-aspartate receptor(NMDAR) antibody encephalitis presents in atypical types and coexists with neuromyelitis optica spectrum disorder or neurosyphilis. ( 28056870 )
2017
21
Aquaporin-4 positive neuromyelitis optica spectrum disorders secondary to thrombopenic purpura: A case report. ( 28079804 )
2017
22
Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial. ( 28831548 )
2017
23
A case of neuromyelitis optica spectrum disorder (NMOSD) with SjAPgren's syndrome manifested only brain involvement by preceding parotitis. ( 28132975 )
2017
24
Retinal segmented layers with strong aquaporin-4 expression suffered more injuries in neuromyelitis optica spectrum disorders compared with optic neuritis with aquaporin-4 antibody seronegativity detected by optical coherence tomography. ( 28057643 )
2017
25
Comparison of brain and spinal cord magnetic resonance imaging features in neuromyelitis optica spectrum disorders patients with or without aquaporin-4 antibody. ( 28427704 )
2017
26
Pregnancy in neuromyelitis optica spectrum disorder: A multicenter study from South China. ( 28017203 )
2017
27
Dimethyl fumarate for patients with neuromyelitis optica spectrum disorder. ( 28747147 )
2017
28
Short segment myelitis as a first manifestation of neuromyelitis optica spectrum disorders. ( 28067584 )
2017
29
First report of persistent dengue-1-associated autoimmune neurological disturbance: neuromyelitis optica spectrum disorder. ( 28748449 )
2017
30
Treatment of neuromyelitis optica and neuromyelitis optica spectrum disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up. ( 28017256 )
2017
31
A protean disease: The phenotypic range of neuromyelitis optica spectrum disorder. ( 28814129 )
2017
32
Syndrome of inappropriate antidiuretic hormone secretion associated with seronegative neuromyelitis optica spectrum disorder. ( 28393003 )
2017
33
Rituximab in Neuromyelitis Optica Spectrum Disorders: Our Experience. ( 28904454 )
2017
34
Clinical commentary on 'Aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder with recurrent short partial transverse myelitis and favorable prognosis: Two new cases', by Wang et al. ( 28580877 )
2017
35
STAT4 Polymorphisms are Associated with Neuromyelitis Optica Spectrum Disorders. ( 28852993 )
2017
36
A treatable cause of myelopathy and vision loss mimicking neuromyelitis optica spectrum disorder: late-onset biotinidase deficiency. ( 28281033 )
2017
37
Cervical cord myelin water imaging shows degenerative changes over one year in multiple sclerosis but not neuromyelitis optica spectrum disorder. ( 28725551 )
2017
38
Efficacy and safety of tacrolimus treatment for neuromyelitis optica spectrum disorder. ( 28400553 )
2017
39
Predictors of response to first-line immunosuppressive therapy in neuromyelitis optica spectrum disorders. ( 28080220 )
2017
40
Can Wernekink commissure syndrome and wall-eyed bilateral internuclear ophthalmoplegia be ascribed to neuromyelitis optica spectrum disorder? ( 28681309 )
2017
41
Screening for onconeural antibodies in neuromyelitis optica spectrum disorders. ( 28068933 )
2017
42
Aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder with recurrent short partial transverse myelitis and favorable prognosis: Two new cases. ( 28580873 )
2017
43
Child Neurology: Neuromyelitis optica spectrum disorders. ( 28069981 )
2017
44
Treatment-resistant neuromyelitis optica spectrum disorders associated with Toxocara canis infection: A case report. ( 28427692 )
2017
45
Deep gray matter atrophy in neuromyelitis optica spectrum disorder and multiple sclerosis. ( 28009104 )
2017
46
Neuromyelitis optica spectrum disorder related tonic spasms responsive to lacosamide. ( 28427706 )
2017
47
Multimodal magnetic resonance imaging in relation to cognitive impairment in neuromyelitis optica spectrum disorder. ( 28835657 )
2017
48
Clinical profile of patients with paraneoplastic neuromyelitis optica spectrum disorder and aquaporin-4 antibodies. ( 28920766 )
2017
49
Primary SjAPgren Syndrome in a Child with a Neuromyelitis Optica Spectrum Disorder. ( 27252507 )
2016
50
Expanding the range of immunopathology in neuromyelitis optica spectrum disorder. ( 27469383 )
2016

Variations for Neuromyelitis Optica Spectrum Disorder

Expression for Neuromyelitis Optica Spectrum Disorder

Search GEO for disease gene expression data for Neuromyelitis Optica Spectrum Disorder.

Pathways for Neuromyelitis Optica Spectrum Disorder

GO Terms for Neuromyelitis Optica Spectrum Disorder

Sources for Neuromyelitis Optica Spectrum Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....